BIOCRYST PHARMACEUTICALS, INC. — Net Income by Fiscal Year
17 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/457b218b-1ea7-4303-86f6-5e33dd718802/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $263.9M | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-012240 |
| FY 2024 | $-88.9M | 2024-01-01 – 2024-12-31 | evidence 0001628280-25-007715 |
| FY 2023 | $-226.5M | 2023-01-01 – 2023-12-31 | evidence 0001628280-24-007205 |
| FY 2022 | $-247.1M | 2022-01-01 – 2022-12-31 | evidence 0001628280-23-005259 |
| FY 2021 | $-184.1M | 2021-01-01 – 2021-12-31 | evidence 0001171843-22-001460 |
| FY 2020 | $-182.8M | 2020-01-01 – 2020-12-31 | evidence 0001171843-21-001411 |
| FY 2019 | $-108.9M | 2019-01-01 – 2019-12-31 | evidence 0001171843-20-001710 |
| FY 2018 | $-101.3M | 2018-01-01 – 2018-12-31 | evidence 0001171843-19-001727 |
| FY 2017 | $-65.8M | 2017-01-01 – 2017-12-31 | evidence 0001171843-18-001855 |
| FY 2016 | $-55.1M | 2016-01-01 – 2016-12-31 | evidence 0001171843-17-001159 |
| FY 2015 | $-43.0M | 2015-01-01 – 2015-12-31 | evidence 0001171843-16-008207 |
| FY 2014 | $-45.2M | 2014-01-01 – 2014-12-31 | evidence 0001171843-15-001186 |
| FY 2013 | $-30.1M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-091609 |
| FY 2012 | $-39.1M | 2012-01-01 – 2012-12-31 | evidence 0001193125-13-100999 |
| FY 2011 | $-56.9M | 2011-01-01 – 2011-12-31 | evidence 0001193125-12-098926 |
| FY 2010 | $-33.9M | 2010-01-01 – 2010-12-31 | evidence 0001193125-12-098926 |
| FY 2009 | $-13.5M | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-098926 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
BIOCRYST PHARMACEUTICALS, INC. — all facts · Revenue · Operating Income